• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Nu Skin Introduces MYND360™, a New Line of Clinically Proven Supplements and Topicals for Mental Well-Being

    10/15/24 8:00:00 AM ET
    $NUS
    Other Pharmaceuticals
    Health Care
    Get the next $NUS alert in real time by email

    MYND360 provides holistic, cognitive support for core areas of mental well-being, including sleep, calm, focus and memory

    Nu Skin Enterprises (NYSE:NUS), a global beauty and wellness leader, today introduced MYND360, a new line of clinically proven nutritional formulas to support core needs for cognitive well-being. MYND360 is the culmination of five years of research and clinical studies, and features six products designed to help users sleep better, manage stress, stay focused and even support a strong memory.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241015775027/en/

    MYND360 features six products designed to help users sleep better, stay focused, manage stress and even support a strong memory. (Photo: Business Wire)

    MYND360 features six products designed to help users sleep better, stay focused, manage stress and even support a strong memory. (Photo: Business Wire)

    "Sleep, stress, memory and mental cognition all have a significant impact on our overall health and well-being," said Steve Hatchett, executive vice president and chief product officer at Nu Skin. "Our global research shows that 93% of consumers have one or more concerns related to sleep, focus or memory. It's also clear that consumers want products that are scientifically proven and shown to be safe and effective through clinical research. We feel this holistic approach will support consumer's desires to live happier, healthier lives."

    The new MYND360 line supports mental well-being in areas that matter most, including calm, focus, sleep and memory.

    • MYND360 Feel Calm: An advanced nutritional formula supports your mood to help you remain calm. Magnolia bark and lemon balm extract work with clinically studied L-Theanine for maintaining healthy cortisol levels and reduced feelings of stress.*
    • MYND360 Mind Full: Multitasking soft gels protect against mental fatigue and support memory and recall. A clinically proven blend of astaxanthin, grape extract and vitamin E helps support healthy memory.*
    • MYND360 Night Time: A clinically supported and carefully formulated sleep supplement with magnesium, melatonin, and natural saffron stigma extract helps you fall asleep faster, stay asleep longer and supports better quality sleep throughout.*
    • MYND360 Sharp Focus: A supplement to support healthy brain function, including mental clarity, concentration, and improved reaction time. Choline, bacopa, B6 and B12 support natural brain function after just one use. A microencapsulated form of caffeine ensures a gradual release to avoid jitters.*
    • MYND360 Relaxing Body Cream: A rich moisturizing cream formulated with topical nutrients like calcium and magnesium absorbs quickly to avoid feeling greasy, and the light, relaxing fragrance helps support a positive mood and enhanced feelings of well-being and relaxation.
    • MYND360 Energizing Hand and Body Wash: An earth-friendly cleanser with green apple ginseng fragrance, along with natural coconut and biodegradable cleansing agents, gently removes dirt, oil and impurities without stripping away skin's hydration.

    As consumer safety is a top concern when creating supplements, Nu Skin uses its exclusive 6S Quality Process to maintain stringent quality, efficacy and safety controls through each stage of development and manufacturing. The process includes a set of highly integrated activities, multiple layers of scientific testing and an extraordinary attention to detail to ensure that each product meets the highest standards and complies with all relevant government requirements.

    Clinical Studies

    Nu Skin scientists commissioned three clinical studies on the key ingredient blends in Night Time, Feel Calm and Mind Full. Scientists studied a unique blend of ingredients in Night Time (magnesium and saffron, without melatonin) designed to improve sleep in a double-blind, placebo-controlled study with 40 healthy adults with self-reported sleep disturbances. The 28-day study found that 89% of participants taking the Night Time blend reported feeling less drowsy when waking up and 96% noted improvement in their sleep quality.*

    Scientists at Princeton Consumer Research observed the impact of Feel Calm's unique ingredient blend (l-theanine, lemon balm, and magnolia bark extract) on stress in a double-blind, placebo-controlled study with 60 healthy adults with moderate stress. This 30-day study found that 98% of participants taking the Feel Calm blend reported improvements in feelings of occasional anxiousness and 93% reported improvements in feelings of melancholy.*

    For memory, Nu Skin scientists studied Mind Full's blend of ingredients (astaxanthin, grape extract, and vitamin E) for its effect on memory in a double-blind, placebo-controlled study with 100 healthy adults with self-reported, memory concerns. The 12-week study found statistical improvement in cognitive performance and episodic memory vs. a placebo. In addition, participants taking the memory blend of ingredients had a statistically significant increase in brain-derived neurotrophic factor (BDNF), a compound produced by the brain related to memory and learning. They also reported a statistically significant decrease in a biomarker of oxidative stress.*

    Sustainability

    In alignment with Nu Skin's 2030 commitment to make all packaging recycled, recyclable, reduced, reusable or renewable, three products in the MYND360 line feature innovative pouches that avoid waste and promote sustainability. These innovative pouches use 81% less plastic and 81% lower carbon emissions from shipping and manufacturing than traditional packaging. Current global sales estimates show the MYND360 pouches will avoid approximately 1.5 tons of plastic a year (these savings do not account for the impact of any consumers who purchase/use the MYND360 pods).

    Availability

    MYND360 products became available Oct. 10 in the U.S. For more information, please visit nuskin.com or the Nu Skin Store on Amazon.

    About Nu Skin

    The Nu Skin Enterprises Inc. (NYSE:NUS) family of companies includes Nu Skin and Rhyz Inc. Nu Skin is an integrated beauty and wellness company, powered by a dynamic affiliate opportunity platform, which operates in nearly 50 markets worldwide. Backed by 40 years of scientific research, the company's products help people look, feel and live their best with brands including Nu Skin® personal care, Pharmanex® nutrition and ageLOC® anti-aging, which includes an award-winning line of beauty device systems. Formed in 2018, Rhyz is a synergistic ecosystem of consumer, technology and manufacturing companies focused on innovation within the beauty, wellness and lifestyle categories.

    * These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20241015775027/en/

    Get the next $NUS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NUS

    DatePrice TargetRatingAnalyst
    1/31/2023$43.00 → $39.00Buy → Hold
    Jefferies
    2/17/2022$47.00 → $50.00Neutral
    DA Davidson
    11/24/2021$43.00 → $49.00Neutral
    Citigroup
    10/6/2021$61.00 → $47.00Neutral
    DA Davidson
    More analyst ratings

    $NUS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Product Officer Hatchett Steven Keith bought $52,855 worth of shares (5,500 units at $9.61), increasing direct ownership by 3% to 167,565 units (SEC Form 4)

    4 - NU SKIN ENTERPRISES, INC. (0001021561) (Issuer)

    11/12/25 4:32:45 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Chief Product Officer Hatchett Steven Keith bought $49,010 worth of shares (6,500 units at $7.54), increasing direct ownership by 4% to 162,065 units (SEC Form 4)

    4 - NU SKIN ENTERPRISES, INC. (0001021561) (Issuer)

    5/28/25 6:26:44 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    $NUS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Nu Skin Launches Prysm iO™: A Revolutionary AI-Powered Platform for Personalized Nutritional Wellness

    Breakthrough intelligent platform measures skin carotenoid levels for antioxidant insights in just 15 seconds, empowering consumers to take control of their nutritional wellness Nu Skin Enterprises Inc. (NYSE:NUS), the world's #1 company for beauty and wellness device systems,* today announced the general consumer availability in the U.S. of Prysm iO™, a breakthrough intelligent nutritional wellness platform designed to deliver a better understanding of how daily nutrition and supplement routines support overall wellness. Prysm iO will launch for consumers in other Nu Skin markets in the coming months. This press release features multimedia. View the full release here: https://www.busine

    4/2/26 4:25:00 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Nu Skin Enterprises Appoints Chelsea Lantz as Interim Chief Financial Officer

    Nu Skin Enterprises, Inc. (NYSE:NUS) today announced the appointment of Chelsea Lantz as interim Chief Financial Officer, effective immediately. The appointment of Lantz comes after James Thomas stepped down as CFO to pursue an outside opportunity. "On behalf of our board, management and the entire Nu Skin team, we thank James for his leadership and significant contributions over 16 years at Nu Skin and wish him and his family well in their future pursuits," said Ryan Napierski, president and CEO. "We have a talented finance team who has led the ongoing work to improve our operational performance and strengthen our balance sheet over the past year. I am excited to work directly with Chels

    3/20/26 4:05:00 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Nu Skin Appoints Chayce Clark as COO

    Clark to expand on his responsibilities as chief legal officer to oversee company operational functions and revenue performance Nu Skin Enterprises Inc. (NYSE:NUS) today announced the appointment of Chayce Clark as chief operating officer effective immediately. Clark will be responsible for leading the company's revenue performance and end-to-end operational execution across the business in addition to maintaining his role as the company's chief legal officer. "Chayce has been a valuable part of our executive team and an important voice in our efforts to become the world's leading intelligent beauty and wellness leadership opportunity platform," said Ryan Napierski, president and CEO. "

    3/9/26 4:05:00 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    $NUS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Lantz Chelsea K

    3 - NU SKIN ENTERPRISES, INC. (0001021561) (Issuer)

    3/30/26 5:57:22 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Director Woodbury Edwina D was granted 14 shares, increasing direct ownership by 0.03% to 42,993 units (SEC Form 4)

    4 - NU SKIN ENTERPRISES, INC. (0001021561) (Issuer)

    3/12/26 5:03:45 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    EVP, President of Global Sales Keisel Justin S was granted 47,059 shares, increasing direct ownership by 42% to 160,170 units (SEC Form 4)

    4 - NU SKIN ENTERPRISES, INC. (0001021561) (Issuer)

    3/9/26 6:14:06 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    $NUS
    SEC Filings

    View All

    SEC Form DEFA14A filed by Nu Skin Enterprises Inc.

    DEFA14A - NU SKIN ENTERPRISES, INC. (0001021561) (Filer)

    4/3/26 2:32:11 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    SEC Form DEF 14A filed by Nu Skin Enterprises Inc.

    DEF 14A - NU SKIN ENTERPRISES, INC. (0001021561) (Filer)

    4/3/26 2:28:12 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Nu Skin Enterprises Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - NU SKIN ENTERPRISES, INC. (0001021561) (Filer)

    3/27/26 4:34:56 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    $NUS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Nu Skin downgraded by Jefferies with a new price target

    Jefferies downgraded Nu Skin from Buy to Hold and set a new price target of $39.00 from $43.00 previously

    1/31/23 6:17:27 AM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    DA Davidson reiterated coverage on Nu Skin Enterprises with a new price target

    DA Davidson reiterated coverage of Nu Skin Enterprises with a rating of Neutral and set a new price target of $50.00 from $47.00 previously

    2/17/22 4:46:52 AM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Citigroup reiterated coverage on Nu Skin Enterprises with a new price target

    Citigroup reiterated coverage of Nu Skin Enterprises with a rating of Neutral and set a new price target of $49.00 from $43.00 previously

    11/24/21 11:03:39 AM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    $NUS
    Leadership Updates

    Live Leadership Updates

    View All

    Nu Skin Enterprises Appoints Chelsea Lantz as Interim Chief Financial Officer

    Nu Skin Enterprises, Inc. (NYSE:NUS) today announced the appointment of Chelsea Lantz as interim Chief Financial Officer, effective immediately. The appointment of Lantz comes after James Thomas stepped down as CFO to pursue an outside opportunity. "On behalf of our board, management and the entire Nu Skin team, we thank James for his leadership and significant contributions over 16 years at Nu Skin and wish him and his family well in their future pursuits," said Ryan Napierski, president and CEO. "We have a talented finance team who has led the ongoing work to improve our operational performance and strengthen our balance sheet over the past year. I am excited to work directly with Chels

    3/20/26 4:05:00 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Nu Skin Appoints Chayce Clark as COO

    Clark to expand on his responsibilities as chief legal officer to oversee company operational functions and revenue performance Nu Skin Enterprises Inc. (NYSE:NUS) today announced the appointment of Chayce Clark as chief operating officer effective immediately. Clark will be responsible for leading the company's revenue performance and end-to-end operational execution across the business in addition to maintaining his role as the company's chief legal officer. "Chayce has been a valuable part of our executive team and an important voice in our efforts to become the world's leading intelligent beauty and wellness leadership opportunity platform," said Ryan Napierski, president and CEO. "

    3/9/26 4:05:00 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Nu Skin Enterprises Appoints James Winett to Board of Directors

    Nu Skin Enterprises (US:NYSE) today announced the appointment of James Winett, a managing member of SIZE Advisory Group, to the company's board of directors. He was elected by shareholders at the annual shareholder meeting for Nu Skin Enterprises. "Jim adds extensive expertise in strategic planning, operations and finance from his many years of consulting experience," said Steven J. Lund, executive chairman of the board. "He will also be an asset to our Rhyz businesses with his background in corporate transactions and advising small businesses and start-ups. We welcome Jim to the board and look forward to tapping into his insights and experience." Winett is a managing member of SIZE Adv

    6/2/25 12:19:00 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    $NUS
    Financials

    Live finance-specific insights

    View All

    Nu Skin Enterprises Reports Fourth Quarter and Full-year 2025 Results Within Guidance

    Company provides initial outlook for Q1 and fiscal year 2026, forecasting a return to revenue growth by year's end Nu Skin Enterprises Inc. (NYSE:NUS) today announced fourth quarter and full-year 2025 revenue and earnings within guidance with more than 50% growth in earnings for 2025. Executive Summary Q4 2025 vs. Prior-year Quarter Revenue $370.3 million; (16.9)% or (10.4)% excluding Mavely 2024 revenue (0.2)% FX impact or $(0.8) million Earnings Per Share (EPS) $0.29 compared to $(0.73) or $0.38 excluding restructuring and other charges Customers 748,796; (10)% Paid Affiliates 129,311; (11)% Sales Leaders 30,045; (

    2/12/26 4:06:00 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Nu Skin Enterprises Announces Quarterly Dividend

    Nu Skin Enterprises, Inc. (NYSE:NUS) today announced its board of directors has declared a quarterly cash dividend of $0.06 per share, which will be paid on Mar. 11, 2026, to shareholders of record on Feb. 27, 2026. About Nu Skin Enterprises Inc. Nu Skin Enterprises Inc. (NYSE:NUS) is an intelligent beauty and wellness company, powered by a dynamic affiliate opportunity platform, which operates in nearly 50 markets worldwide. Backed by more than 40 years of scientific research, the company's products help people look, feel and live their best with our newly introduced Prysm iO intelligent wellness platform, an award-winning line of beauty device systems and trusted brands in personal ca

    2/12/26 4:05:00 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Nu Skin Enterprises to Announce Fourth Quarter and Full Year 2025 Financial Results

    Nu Skin Enterprises Inc. (NYSE:NUS) today announced it will release fourth quarter and full year 2025 results after the market closes on Thursday, Feb. 12. The Nu Skin management team will host a conference call with the investment community later that same day at 5 p.m. ET. During the call, management will discuss recent results and upcoming business initiatives. The webcast of the conference call, including the financial information presented, will be available on the investor relations page of the company's website at ir.nuskin.com. A replay of the webcast will be available at the same location through Thursday, Feb. 26. About Nu Skin Enterprises Inc. The Nu Skin Enterprises Inc. (

    1/14/26 4:05:00 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    $NUS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Nu Skin Enterprises Inc.

    SC 13G/A - NU SKIN ENTERPRISES, INC. (0001021561) (Subject)

    11/12/24 4:47:17 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Amendment: SEC Form SC 13G/A filed by Nu Skin Enterprises Inc.

    SC 13G/A - NU SKIN ENTERPRISES, INC. (0001021561) (Subject)

    11/6/24 10:20:59 AM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Amendment: SEC Form SC 13G/A filed by Nu Skin Enterprises Inc.

    SC 13G/A - NU SKIN ENTERPRISES, INC. (0001021561) (Subject)

    11/4/24 10:21:31 AM ET
    $NUS
    Other Pharmaceuticals
    Health Care